Table 2. Pharmacokinetic study of UBS109 administered by i.p.
| UBS109 IP dose (15mg/kg) | ||||||
|---|---|---|---|---|---|---|
| Mice | T ½ (hr) | Tmax (hr) | Cmax (ng/mL) | AUClast (hr*ng/mL) | AUCinf (hr*ng/mL) | Extrapolated (%) |
| 1 | NR | 0.25 | 398 | 813 | NR | NR |
| 2 | 1.97 | 0.25 | 623 | 116 | 124 | 6.15 |
| 3 | NR | 0.25 | 835 | 1061 | NR | NR |
| Mean | 1.97 | 0.25 | 618.67 | 664 | 124 | 6.15 |
| SD | NA | 0.00 | 218.53 | 490 | NA | NA |
Abbreviations: NR = Not reported due to insufficient characterization of the terminal phase of the plasma-concentration profile (Rsq < 0.9); NA = Not applicable; t½ = terminal half-life; AUC0-∞ = area under a concentration of analyte vs. time calculated using zero to infinity; AUC0-last = computed from time zero to the time of the last positive Y value; Cmax = the peak or maximum concentration; Tmax = the time of peak concentration; SD = standard deviation.